Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Checking physical care of people on risperidone long term injectable depot.

Najim H, Islam N.

Psychiatr Danub. 2013 Sep;25 Suppl 2:S171-3.

2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

Explicit review of risperidone long-acting injection prescribing practice.

Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.

J Clin Pharm Ther. 2011 Dec;36(6):651-63. doi: 10.1111/j.1365-2710.2010.01219.x. Epub 2010 Nov 5.

PMID:
22023342
4.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
5.

Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain.

Olivares JM, Rodriguez-Martinez A, Burón JA, Alonso-Escolano D, Rodriguez-Morales A; e-STAR Study Group.

Appl Health Econ Health Policy. 2008;6(1):41-53.

PMID:
18774869
6.
7.

Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Masand PS, Gupta S.

Drugs Aging. 2003;20(15):1099-110. Review.

PMID:
14651433
8.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
9.

Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.

Lai YC, Huang MC, Chen CH, Tsai CJ, Pan CH, Chiu CC.

Psychiatry Clin Neurosci. 2009 Aug;63(4):440-8. doi: 10.1111/j.1440-1819.2009.01977.x. Epub 2009 Apr 27.

10.

[Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].

Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.

Encephale. 2007 Dec;33(6):973-81. doi: 10.1016/j.encep.2006.07.003. Epub 2007 Sep 4. French.

PMID:
18789790
11.

Long-acting risperidone in stable patients with schizoaffective disorder.

Mohl A, Westlye K, Opjordsmoen S, Lex A, Schreiner A, Benoit M, Bräunig P, Medori R.

J Psychopharmacol. 2005 Sep;19(5 Suppl):22-31.

PMID:
16144783
12.

Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration.

Ren XS, Crivera C, Sikirica M, Dirani R, Qian S, Kazis LE.

J Clin Pharm Ther. 2011 Jun;36(3):383-9. doi: 10.1111/j.1365-2710.2010.01211.x. Epub 2010 Nov 10.

PMID:
21062329
13.

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.

Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.

Pharmacopsychiatry. 2007 Nov;40(6):257-63.

PMID:
18030649
14.

Clinical review of a long-acting, injectable formulation of risperidone.

Knox ED, Stimmel GL.

Clin Ther. 2004 Dec;26(12):1994-2002. Review.

PMID:
15823763
15.

One-year treatment continuation in patients prescribed risperidone long-acting injection in New Zealand: a retrospective study.

Wheeler A, Vanderpyl J, Carswell C, Stojkovic M, Robinson E.

Clin Schizophr Relat Psychoses. 2012 Jul;6(2):61-8. doi: 10.3371/CSRP.6.2.3.

PMID:
22776632
16.

Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.

Martin SD, Libretto SE, Pratt DJ, Brewin JS, Huq ZU, Saleh BT.

Curr Med Res Opin. 2003;19(4):298-305.

PMID:
12841922
17.

Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone.

Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M.

J Clin Psychiatry. 2004 Apr;65(4):531-6. Erratum in: J Clin Psychiatry. 2004 Aug;65(8):1150.

PMID:
15119916
18.

Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.

Barrio P, Batalla A, Castellví P, Hidalgo D, García M, Ortiz A, Grande I, Pons A, Parellada E.

Int Clin Psychopharmacol. 2013 Jul;28(4):164-70. doi: 10.1097/YIC.0b013e3283611cc3.

PMID:
23587986
19.

Improved symptom control, functioning and satisfaction in French patients treated with long-acting injectable risperidone.

Llorca PM, Bouhours P, Moreau-Mallet V; French investigators group.

Encephale. 2008 Apr;34(2):170-8. doi: 10.1016/j.encep.2007.06.004. Epub 2007 Nov 1.

PMID:
18597725
20.

Risperidone long-acting therapy prescribing patterns and their impact on early discontinuation of treatment in a large Medicaid population.

Boaz TL, Constantine RJ, Robst J, Becker MA, Howe AM.

J Clin Psychiatry. 2011 Aug;72(8):1079-85. doi: 10.4088/JCP.09m05348yel. Epub 2010 Oct 19.

PMID:
21034690

Supplemental Content

Support Center